Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis

Tyrosine kinase inhibitors are considered for use in patients with hepatocellular carcinoma (HCC) refractory to transarterial chemoembolization (TACE). The aim of the present retrospective study was to identify factors associated with progression-free survival (PFS) and to evaluate the indications f...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncol Lett
Auteurs principaux: Shimose, Shigeo, Kawaguchi, Takumi, Tanaka, Masatoshi, Iwamoto, Hideki, Miyazaki, Ken, Moriyama, Etsuko, Suzuki, Hiroyuki, Niizeki, Takashi, Shirono, Tomotake, Nakano, Masahito, Suga, Hideya, Yamaguchi, Taizo, Yokokura, Yoshinori, Noguchi, Kazunori, Koga, Hironori, Torimura, Takuji
Format: Artigo
Langue:Inglês
Publié: D.A. Spandidos 2020
Sujets:
Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7400966/
https://ncbi.nlm.nih.gov/pubmed/32782543
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2020.11758
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires